Aberdeen Village: Psychotropic Medication Violations - KS
That is what federal inspectors found at Aberdeen Village on February 10, 2026.
The resident, identified in inspection records as Resident 20, was admitted to the facility on April 15, 2025, already taking Quetiapine Fumarate, the generic form of Seroquel, a powerful antipsychotic typically prescribed for schizophrenia, bipolar disorder, and major depressive episodes. Her diagnoses on file included Alzheimer's disease, a prior stroke, insomnia, and major depressive disorder. A cognitive assessment completed in January 2026 gave her a score of four on a standard mental status scale, indicating severe cognitive impairment. She was otherwise documented as independent in meals, hygiene, toileting, dressing, and movement. The same assessment noted no behavioral symptoms during the observation period.
She was receiving 12.5 milligrams of Seroquel daily under a physician order renewed on May 15, 2025. The stated reason on that order: unspecified dementia with psychotic disturbances.
Dementia is not an approved indication for antipsychotic use under Centers for Medicare and Medicaid Services guidelines. The facility's own nursing staff said as much during the inspection.
Licensed Nurse G told inspectors on the afternoon of February 10 that antipsychotic medication was not indicated for dementia treatment and that the medication required a psychiatric reason or diagnosis for use. Administrative Nurse D said she had spoken with the resident's family representative multiple times about changing the medication's documented indication, but the representative refused. She acknowledged that dementia was not an appropriate indication for the drug but noted the resident had arrived at the facility already on it.
That explanation did not satisfy what inspectors were looking for. The question was not only why the resident was taking the medication, but whether anyone at the facility had documented a legitimate clinical reason for continuing it, and whether anyone was systematically watching for signs that it was harming her.
Neither record existed.
A review of Resident 20's electronic medical records found no behavioral monitoring documentation related to her antipsychotic use. Her care plan, initiated in late April 2025, noted she had exhibited behaviors of resisting care and yelling out, connected to depression, anxiety, and dementia, and that she was taking Quetiapine in relation to those behaviors. Staff were instructed to monitor for medication side effects. But the care plan contained no psychiatric indications for the Quetiapine prescription. The section that would have documented the clinical rationale for an antipsychotic, the behavioral targets the medication was meant to address, the symptoms it was supposed to reduce, was blank.
A facility consultant pharmacist had reviewed Resident 20's medications monthly from May 2025 through February 2026. In December 2025, the pharmacist recommended a gradual dose reduction to bring the prescription to the lowest possible effective dose. The physician declined, citing risk of decompensation. That exchange was documented. What was not documented, across any of those monthly reviews, was a recommendation addressing whether the antipsychotic had an appropriate CMS-approved indication at all. The pharmacist flagged the dose. Nobody flagged the diagnosis.
On February 10, when inspectors asked the facility to provide a documented rationale for continuing the Quetiapine prescription without an appropriate CMS indication, the facility could not produce one.
The consultant pharmacist, identified as Consultant GG, told inspectors that the resident had come to the facility on the medication and that her representative had refused to allow changes or discontinuation. She said the resident required the medication for dementia-related hallucinations and delusions. That clinical claim, hallucinations and delusions, did not appear anywhere in the care plan, in the behavioral monitoring record, or in the physician order, which listed only "unspecified dementia with psychotic disturbances." And the behavioral monitoring record that would have documented whether those hallucinations and delusions were actually occurring, or responding to treatment, did not exist.
Antipsychotic medications carry serious risks for elderly patients with dementia. They are associated with increased risk of stroke, accelerated cognitive decline, falls, and death. The Food and Drug Administration has required black-box warnings on antipsychotics used in this population for more than two decades. CMS requires nursing facilities to document specific, approved psychiatric indications before administering these drugs, and to conduct gradual dose reduction attempts unless clinically contraindicated, precisely because the risks are substantial and the population is vulnerable.
Resident 20's cognitive assessment score of four placed her at the severe end of the impairment scale. She could not advocate for herself. Her family representative, who had the authority to make decisions on her behalf, had declined to allow medication changes. That refusal may have been made in good faith, and it may have reflected real clinical history the facility knew about but did not document. But the facility's obligation does not end when a family member says no. The obligation is to document the clinical picture clearly, to pursue appropriate indications, and to demonstrate through monitoring records that the medication is doing what it is supposed to do without causing harm.
None of that happened here.
The facility's own drug regimen review policy, revised in April 2025, the same month Resident 20 was admitted, stated that the facility would collaborate with a licensed pharmacist to conduct ongoing monthly medication reviews to identify irregularities and ensure safe medication practices. Ten months of monthly reviews passed. The pharmacist recommended a dose reduction once. The indication problem was never raised in writing.
Inspectors cited the violation at a level of minimal harm or potential for actual harm, which places it in the lower tier of severity under federal inspection standards. The citation did not allege that Resident 20 had been injured. When inspectors observed her the day before the inspection concluded, she was calm, engaged, and showed no behavioral symptoms. Whether the medication was helping her, harming her, or doing nothing at all was unknowable, because nobody had been tracking it.
That is the condition she was in when inspectors left: still on the medication, still without a documented psychiatric indication, still without a behavioral monitoring record, and still dependent on a facility that had spent ten months unable to explain in writing why she was taking a drug that carries a federal warning for patients exactly like her.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Aberdeen Village from 2026-02-10 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: August 5, 2026 · Our methodology
ABERDEEN VILLAGE in OLATHE, KS was cited for violations during a health inspection on February 10, 2026.
That is what federal inspectors found at Aberdeen Village on February 10, 2026.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.